Marker Therapeutics Inc./$MRKR
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Ticker
$MRKR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
5
ISIN
US57055L2060
Website
MRKR Metrics
BasicAdvanced
$18M
-
-$1.34
1.45
-
Price and volume
Market cap
$18M
Beta
1.45
52-week high
$2.09
52-week low
$0.95
Average daily volume
171K
Financial strength
Current ratio
6.794
Quick ratio
6.457
Profitability
Gross margin (TTM)
-146.28%
Net profit margin (TTM)
-224.45%
Operating margin (TTM)
-223.40%
Effective tax rate (TTM)
-0.39%
Revenue per employee (TTM)
$1,140,000
Management effectiveness
Return on assets (TTM)
-51.17%
Return on equity (TTM)
-97.30%
Valuation
Price to revenue (TTM)
2.627
Price to book
1.21
Price to tangible book (TTM)
1.21
Price to free cash flow (TTM)
-1.19
Free cash flow yield (TTM)
-84.02%
Free cash flow per share (TTM)
-131.91%
Growth
Revenue change (TTM)
71.53%
Earnings per share change (TTM)
109.77%
3-year revenue growth (CAGR)
37.19%
3-year earnings per share growth (CAGR)
-36.23%
10-year earnings per share growth (CAGR)
-18.98%
MRKR News
AllArticlesVideos
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
GlobeNewsWire·2 weeks ago
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
GlobeNewsWire·1 month ago
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Marker Therapeutics Inc. stock?
Marker Therapeutics Inc. (MRKR) has a market cap of $18M as of July 04, 2025.
What is the P/E ratio for Marker Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Marker Therapeutics Inc. (MRKR) stock is 0 as of July 04, 2025.
Does Marker Therapeutics Inc. stock pay dividends?
No, Marker Therapeutics Inc. (MRKR) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Marker Therapeutics Inc. dividend payment date?
Marker Therapeutics Inc. (MRKR) stock does not pay dividends to its shareholders.
What is the beta indicator for Marker Therapeutics Inc.?
Marker Therapeutics Inc. (MRKR) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.